On October 28, 2019 Lineage Cell Therapeutics, Inc.(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that it will participate in Solebury Trout’s KOL Event for analysts and investors on November 15, 2019 at 11am ET in New York City at the offices of White & Case, LLP (Press release, Lineage Cell Therapeutics, OCT 28, 2019, View Source [SID1234549908]). Lineage will begin with a corporate overview from Brian M. Culley, Chief Executive Officer and Edward D. Wirth, III, MD, PhD, Chief Medical Officer, which will be followed by presentations from Lineage therapeutic area experts Allen C. Ho, MD, FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research and John Steeves, BSc, PhD, Emeritus Principal Investigator, ICORD and Professor, Department of Neuroscience at the University of British Columbia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live webcast of the Lineage presentations on the Events and Presentations section of Lineage’s website and an archived presentation will be available for 30 days.